{"nctId":"NCT01908140","briefTitle":"Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)","startDateStruct":{"date":"2013-09"},"conditions":["Chronic Obstructive Pulmonary Disease (COPD)"],"count":933,"armGroups":[{"label":"Aclidinium Bromide / Formoterol Fumarate","type":"EXPERIMENTAL","interventionNames":["Drug: Aclidinium Bromide / Formoterol Fumarate"]},{"label":"Salmeterol / Fluticasone propionate","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Salmeterol / Fluticasone"]}],"interventions":[{"name":"Aclidinium Bromide / Formoterol Fumarate","otherNames":[]},{"name":"Salmeterol / Fluticasone","otherNames":["Seretide","Advair"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Adult male or non-pregnant, non-lactating female aged ≥40.\n* Current or ex-cigarette smoker, with a smoking history of at least 10 pack-years\n* Patients with a clinical diagnosis of COPD according to GOLD guidelines 2013, with a post-bronchodilator FEV1 \\<80%, and FEV1/FVC \\< 70% at Screening Visits\n* Symptomatic patients with a COPD assessment test (CAT) ≥10 at Screening and Randomisation Visits\n* Patient must be able to perform repeatable pulmonary function testing for FEV1 according to ATS/ERS 2005 criteria at Screening Visits\n* Patients eligible and able to participate in the trial and who consent to do so in writing after the purpose and nature of the investigation have been explained\n\nExclusion Criteria:\n\n* History or current diagnosis of asthma\n* Development of a respiratory tract infection or COPD exacerbation within 6 weeks (or 3 months if hospitalisation was required) before the Screening Visit or during the run-in period\n* Clinically significant respiratory conditions\n* Type I or uncontrolled Type II diabetes, uncontrolled hypo- or hyperthyroidism, hypokalaemia, or hyperadrenergic state, uncontrolled or untreated hypertension\n* Patients who, in the investigator's opinion, may need to start a pulmonary rehabilitation programme during the study and/or patients who started/finished it within 3 months prior to Screening Visit\n* Use of long-term oxygen therapy (≥15 hours/day)\n* Patients treated on daily basis with triple therapy (LABA+LAMA+ICS) within 4 weeks prior to the Screening Visit\n* Patient who does not maintain regular day/night, waking/sleeping cycles including night shift workers\n* Clinically significant cardiovascular conditions\n* Patient with clinically relevant abnormalities in the results of the clinical laboratory tests, ECG parameters or in the physical examination at the Screening Visit\n* Patient with a history of hypersensitivity reaction to inhaled anticholinergics, sympathomimetic amines, or inhaled medication or any component thereof (including report of paradoxical bronchospasm)\n* Patient with known narrow-angle glaucoma, symptomatic bladder neck obstruction, acute urinary retention, or patients with symptomatic non-stable prostatic hypertrophy\n* Patient with known non-controlled history of infection with human immunodeficiency virus (HIV) and/or active hepatitis\n* History of malignancy of any organ system (including lung cancer), treated or untreated, within the past 5 years other than basal or squamous cell skin cancer\n* Patient with any other serious or uncontrolled physical or mental dysfunction\n* Patient with a history (within 2 years prior to Screening Visit) of drug and/or alcohol abuse that may prevent study compliance based on investigator judgment\n* Patient unlikely to be cooperative or that can't comply with the study procedures\n* Patient treated with any investigational drug within 30 days (or 6 half-lives, whichever is longer) prior to Screening Visit\n* Patient who intend to use any concomitant medication not permitted by this protocol or who have not undergone the required stabilization periods for prohibited medication\n* Any other conditions that, in the investigator's opinion, might indicate the patient to be unsuitable for the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Peak Forced Expiratory Volume in One Second (FEV1) at Week 24","description":"Peak FEV1 define at the highest value observed in the 3h after the morning IMP administration","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.655","spread":"0.011"},{"groupId":"OG001","value":"1.562","spread":"0.011"}]}]}]},{"type":"SECONDARY","title":"Transition Dyspnoea Index (TDI) Focal Score at Week 24","description":"The TDI includes the same 3 categories as BDI and 7 ratings indicating the magnitude of the change from baseline in each category: from -3 (\"major deterioration\") to zero (\"no change\") to +3 (\"major improvement\"). Category scores are added to compute the Focal Score (from -9 to 9)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"0.17"},{"groupId":"OG001","value":"1.9","spread":"0.17"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":35,"n":467},"commonTop":["Chronic obstructive pulmonary disease","Headache","Nasopharyngitis"]}}}